InMed Pharmaceuticals reported Q3 FY2026 financial results with a $3.0 million net loss from continuing operations and $5.2 million in cash, alongside preclinical data supporting INM-901 for Alzheimer's neuroinflammation.
Key takeaways
Net loss from continuing operations $2.8 million for Q3 FY2026, up from $2.1 million prior year.
R&D expenses rose to $1.0 million from $0.4 million due to INM-901 external contractors.
Cash and equivalents fell to $5.2 million as of March 31, 2026 from $10.8 million at June 30, 2025.
BayMedica commercial operations to wind down by June 30, 2026, classified as discontinued.
INM-901 showed dose-dependent reduction of IL-6 and IL-8 in human 3D brain organoid Alzheimer's models.
Common shares outstanding increased to 3,314,063 from 2,002,186 year-over-year.